The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
176
Change from baseline in the total score of the 7 items of the Positive and Negative Symptom Scale (PANSS) positive symptom subscale for lamotrigine vs. placebo at Week 12.
Time frame: 12 Weeks
Change from baseline in the PANSS total score at Week 12; Change from baseline in the Scale for the Assessment of Negative Symptoms (SANS) at Week 12; Change from baseline in the Clinical Global Impression-Severity of Illness (CGI-S) score at Week 12.
Time frame: 12 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Garden Grove, California, United States
GSK Investigational Site
La Mesa, California, United States
GSK Investigational Site
National City, California, United States
GSK Investigational Site
Oceanside, California, United States
GSK Investigational Site
Rosemead, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Hartford, Connecticut, United States
GSK Investigational Site
Maitland, Florida, United States
GSK Investigational Site
North Miami, Florida, United States
...and 22 more locations